Bavarian Nordic (XTRA:BV3) - Cotización, noticias y análisis

Resumen de acción BV3

Develops, manufactures, and commercializes life-saving vaccines.

BV3 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 60.1% por debajo de nuestra estimación de su valor justo

Ha pasado a ser rentable este año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 16.8% al año durante los próximos 3 años

Alto nivel de ganancias no monetarias

Acciones altamente ilíquidas

Los accionistas han sido diluidos en el último año

Competidores de Bavarian Nordic A/S

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€782.3m

2invest

XTRA:2INV

€49.7m

Dermapharm Holding

XTRA:DMP

€2.0b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	kr.25.30
52 Week High	kr.35.80
52 Week Low	kr.23.12
Beta	1.29
1 Month Change	0%
3 Month Change	-3.80%
1 Year Change	-12.61%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-58.71%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BV3	DE Biotechs	Mercado DE
7D	0%	0.6%	-0.4%
1Y	-12.6%	-25.6%	4.2%

Rentabilidad vs. Industria: BV3 superó al sector German Biotechs , que obtuvo un rendimiento del -21.1% el año pasado.

Rentabilidad vs. Mercado: BV3 obtuvo unos resultados inferiores a los del mercado German, que fue del -0.3% el año pasado.

Volatilidad de los precios

Is BV3's price volatile compared to industry and market?
BV3 volatility
BV3 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.1%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: BV3 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BV3 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	1,354	Paul Chaplin	www.bavarian-nordic.com

Resumen de fundamentos de Bavarian Nordic A/S

¿Cómo se comparan los beneficios e ingresos de Bavarian Nordic con su capitalización de mercado?
Estadísticas fundamentales de BV3
Capitalización bursátil	€1.44b
Beneficios(TTM)	€144.27m
Ingresos (TTM)	€741.69m

10.0x

Ratio precio-beneficio (PE)

1.9x

Ratio precio-ventas (PS)

¿Está BV3 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BV3
Ingresos	kr.5.53b
Coste de los ingresos	kr.1.84b
Beneficio bruto	kr.3.69b
Otros gastos	kr.2.62b
Beneficios	kr.1.08b

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

Nov 16, 2023

Beneficios por acción (BPA)	13.84
Margen bruto	66.78%
Margen de beneficio neto	19.45%
Ratio deuda/patrimonio	0.2%

¿Cómo se ha desempeñado BV3 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BV3

Recompensas

Análisis de riesgos

Competidores de Bavarian Nordic A/S

XTRA:BIO3

€1.4b

XTRA:FYB

€782.3m

XTRA:2INV

€49.7m

XTRA:DMP

€2.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Recent updates

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Executive Officer Tommi Kainu has left the company

High number of new directors

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Bavarian Nordic A/S

10.0x

1.9x

Beneficios e Ingresos